To assess the possibility of TRAIL as a new treatment strategy against NSCLC, we evaluated the sensitivity of two NSCLC cell lines to TRAIL by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. Here, TNFSF10 is linked to non-small cell lung carcinoma.